Ireland
--:--IST
Latest
Clinical Trials in Portugal / NCT05473299
Active, not recruiting Not applicable

Xeltis Hemodialysis Access Graft: aXess Pivotal Study

NCT05473299 · tracked via the Priya Life Science Portugal tracker
Sponsor
Phase
Not applicable
Started
2022-11-04
Last updated
2025-07-18

Condition(s) studied

End-stage Renal Disease

Investigational drug(s) / intervention(s)

Xeltis Hemodialysis Access (aXess) graft

Xeltis Hemodialysis Access (aXess) graft: The aXess graft is a sterile, regenerative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess graft is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.

Study summary

A prospective, single arm, non-randomized pivotal study to evaluate the safety and performance of the Xeltis hemodialysis access graft in subjects older than 18 years with end-stage renal disease, who plan to undergo hemodialysis for at least the first 6 months after study access creation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Subjects with end-stage renal disease (ESRD) who require placement of an AVG in the upper extremity to start or maintain hemodialysis therapy 2. At least 18 years of age at screening 3. Suitable anatomy (e.g. a target vein with a minimum diameter of 5mm) for the implantation of an aXess graft 4. The patient, or legal representative, has been informed about the nature of the study, agrees to its provisions, and has provided written informed consent 5. The patient has been informed and agrees to pre- and post- procedure follow-up 6. Life expectancy of at least 12 months Exclusion Criteria: 1. History or evidence of severe cardiac disease (NYHA Functional Class IV and/or EF \<25%), myocardial infarction within six months of study enrolment, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina 2. Uncontrolled or poorly controlled diabetes 3. Abnormal blood values that could influence patient recovery and or/ graft hemostasis 4. Reduced liver function, defined as: \>2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) \>1.5 or prothrombin time (PT) \>18 seconds 5. Any active local or systemic infection 6. Known heparin-induced thrombocytopenia 7. Known active bleeding disorder and/or any coagulopathy or thromboembolic disease 8. Allergies to study device (nitinol) or agents/medication, such as contrast agents or aspirin, that can't be controlled medically 9. Anticipated renal transplant within 6 months 10. Known or suspected central vein obstruction on the side of planned graft implantation 11. Previous dialysis access graft in the operative limb unless the aXess graft can be placed more proximally than the previous failed graft 12. Previous enrolment in this study 13. Subject is participating in another study 14. Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives 15. Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit Intra-operative exclusion criteria: 1\. Unsuitable anatomy to implant the aXess graft (e.g. target vein and/or artery diameter smaller than anticipated; severe calcification)

Primary outcome measure(s)

Trial sites (22)

FacilityCityRegionStatus
AZ Sint Jan Brugge Bruges Belgium
ZOL Genk Genk Belgium
UZ Ghent Ghent Belgium
Universitätsklinikum Köln Cologne Germany
LAIKO General Hospital of Athens Athens Greece
University General Hospital of Patras Pátrai Greece
Ospedali Riuniti Torrette di Ancona Ancona Italy
Policlinico di Bari Bari Italy
Policlinico di Sant'Orsola Bologna Italy
Università degli studi di Padova / Azienda ospedaliera di Padova Padova Italy
Universita degli studi dell'Insubria Varese Italy
Pauls Stradins Clinical University Hospital Riga Latvia
Private hospital MedPolonia Poznan Poznan Poland
The Lower Silesia Center of Heart Diseases MEDINET Wroclaw Poland
Santa Maria Hospital Lisbon Portugal
Grupo de Estudos Vasculares Porto Portugal
DaVita Sacavém Sacavém Portugal
Bellvitge University Hospital Barcelona Spain
Hospital Clínic de Barcelona Barcelona Spain
Hospital Universitario de la Ribera Valencia Spain
University Hospitals Birmingham - QE Birmingham United Kingdom
Queen Elizabeth University Hospital Glasgow United Kingdom

More Xeltis trials in Portugal

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05473299 on ClinicalTrials.gov ↗ ← All trials in Portugal